BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martin I, Ireland H, Baldomero H, Dominici M, Saris DB, Passweg J. The Survey on Cellular and Engineered Tissue Therapies in Europe in 2013. Tissue Engineering Part A 2016;22:5-16. [DOI: 10.1089/ten.tea.2015.0416] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Wang W, Deng D, Wang B, Zhou G, Zhang W, Cao Y, Zhang P, Liu W. Comparison of Autologous, Allogeneic, and Cell-Free Scaffold Approaches for Engineered Tendon Repair in a Rabbit Model-A Pilot Study. Tissue Engineering Part A 2017;23:750-61. [DOI: 10.1089/ten.tea.2016.0447] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
2 Crivelli B, Chlapanidas T, Perteghella S, Lucarelli E, Pascucci L, Brini AT, Ferrero I, Marazzi M, Pessina A, Torre ML; Italian Mesenchymal Stem Cell Group (GISM). Mesenchymal stem/stromal cell extracellular vesicles: From active principle to next generation drug delivery system. J Control Release. 2017;262:104-117. [PMID: 28736264 DOI: 10.1016/j.jconrel.2017.07.023] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 14.6] [Reference Citation Analysis]
3 Kočí Z, Boráň T, Krůpa P, Kubinová Š. The Current State of Advanced Therapy Medicinal Products in the Czech Republic. Hum Gene Ther Clin Dev 2018;29:132-47. [PMID: 29869533 DOI: 10.1089/humc.2018.035] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Li Y, Hao J, Hu Z, Yang YG, Zhou Q, Sun L, Wu J. Current status of clinical trials assessing mesenchymal stem cell therapy for graft versus host disease: a systematic review. Stem Cell Res Ther 2022;13:93. [PMID: 35246235 DOI: 10.1186/s13287-022-02751-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Guzzi EA, Tibbitt MW. Additive Manufacturing of Precision Biomaterials. Adv Mater 2020;32:e1901994. [PMID: 31423679 DOI: 10.1002/adma.201901994] [Cited by in Crossref: 65] [Cited by in F6Publishing: 48] [Article Influence: 32.5] [Reference Citation Analysis]
6 Ireland H, Gay MH, Baldomero H, De Angelis B, Baharvand H, Lowdell MW, Passweg J, Martin I. The survey on cellular and tissue-engineered therapies in Europe and neighboring Eurasian countries in 2014 and 2015. Cytotherapy 2018;20:1-20. [DOI: 10.1016/j.jcyt.2017.08.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
7 Gay MHP, Baldomero H, Farge-Bancel D, Robey PG, Rodeo S, Passweg J, Müller-Gerbl M, Martin I. The Survey on Cellular and Tissue-Engineered Therapies in Europe in 2016 and 2017. Tissue Eng Part A 2021;27:336-50. [PMID: 32680446 DOI: 10.1089/ten.TEA.2020.0092] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
8 Ayerst BI, Merry CLR, Day AJ. The Good the Bad and the Ugly of Glycosaminoglycans in Tissue Engineering Applications. Pharmaceuticals (Basel) 2017;10:E54. [PMID: 28608822 DOI: 10.3390/ph10020054] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]